Company InfoNewsInvestor InformationResearchDevelopmentCareersBusiness DevelopmentResourcesDrugs databaseBack to the home pageSearch  
Drugs database
Drugs A-Z

Brands A-Z

Drugs by categories

Drugs by manufacturer

Drugs by packager

Antibiotics for sale

Online Viagra bestellen in Nederland

Home / Drugs / Starting with F / Fludarabine

Fludarabine (marketed as fludarabine phosphate under the trade name Fludara) is a chemotherapy drug used in the treatment of hematological malignancies. [Wikipedia]
CategoriesAntineoplastic Agents
Immunosuppressive Agents
Antimetabolites, Antineoplastic
ManufacturersGenzyme corp
Actavis totowa llc
App pharmaceuticals llc
Hospira inc
Sandoz inc
Teva parenteral medicines inc
Sanofi aventis us llc
PackagersAPP Pharmaceuticals
Bayer Healthcare
Ben Venue Laboratories Inc.
Ebewe Pharma
Genzyme Inc.
Hospira Inc.
Sagent Pharmaceuticals
Sanofi-Aventis Inc.
Sicor Pharmaceuticals
Teva Pharmaceutical Industries Ltd.
Fludarabine 5'-monophosphate
Fludarabine monophosphate
Fludarabine phosphate


For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen


Fludarabine is a chemotherapy drug used in the treatment of chronic lymphocytic leukemia. It acts at DNA polymerase alpha, ribonucleotide reductase and DNA primase, results in the inhibition of DNA synthesis, and destroys the cancer cells.

mechanism of action

Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis. The mechanism of action of this antimetabolite is not completely characterized and may be multi-faceted.


Bioavailability is 55% following oral administration.

half life

20 hours

drug interactions

Dipyridamole: Dipyridamole may decrease the effect of fludarabine.

Pentostatin: Unacceptable pulmonary toxicity

Trastuzumab: Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.